Renowned by Expertise and Versatility | Wallaby Medical's pNOVUS™ 17 Microcatheter has been approved in China, USA and Japan

Renowned by Expertise and Versatility

August 4, 2023, Shanghai (China), Laguna Hills (CA, USA), Bochum (Germany) - The pNOVUS™ 17 Microcatheter, which was independently developed by Wallaby Medical, has been approved for marketing by the National Medical Products Administration (NMPA) of China. Before the NMPA approval, it had obtained 510K clearance of the US Food and Drug Administration (FDA) and approval of the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.

After the acquisition of the German company Phenox, the pNOVUS™ 17 Microcatheter is the first product collectively launched by Wallaby Medical and Phenox to the global market, as the third member of the pNOVUS™ family.

In Latin, NOVUS means “brand new", which represents Wallaby Medical's commitment to providing customers with a refreshed experience and trustworthy quality as always for each pNOVUS™ microcatheter.

Collaborating against Stroke

Wallaby Medical is committed to providing precise, efficient and reliable one-stop services for all stroke patients. After the pNOVUS™ Microcatheter is launched, it can be used in combination with the Pilote™ Distal Access Guide Catheter (long sheath), Esperance® Distal Access Catheter, and Avenir Coil System, which have all been approved in China, to form a portfolio and clinical solution embodying the innovative mindset of Wallaby Medical. In the future, Wallaby Medical will keep enriching its stroke portfolio in China through independent innovation and introduction of overseas state-of-the-art products!

Empowering with Medical Technology

According to the China Stroke Report 2019, stroke has become one of the main causes of death in China; The Healthy China 2030 Outline also emphasizes stroke prevention and control as a national strategy.

By taking the responsibilities of improving the full-process management of stroke in China and contributing to the implementation of Healthy China 2030 strategy as its own, Wallaby Medical is committed to empowering the development of neurointervention in China and becoming the game-changer of the global stroke solutions through global operation and M&A, innovative products, and diversified collaborations!

Aspiring to "become the medical technology company that saves the most lives affected by stroke", Wallaby Medical will leverage its innovation, products and revolutionary treatment concept to win the respect and recognition for Chinese brands, and benefit more stroke patients.